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Available online 20 February 2008Hyperphenylalaninemia is a group of autosomal recessive disorders caused by a wide range of phenylalanine
hydroxylase (PAH) gene variants. To study the effects of mutations on PAH activity, we have reproduced ﬁve
mutations (p.N223Y, p.R297L, p.F382L, p.K398N and p.Q419R) that we recently identiﬁed in a population of
Southern Italy. Transient expression of mutant full-length cDNAs in human HEK293 cells yielded PAH variants
whose L-phenylalanine hydroxylase activity was between 40% and 70% that of the wild-type enzyme.
Moreover, Western blot analysis revealed a 50-kD monomer in all mutants thereby indicating normal
synthesis of the mutant proteins. Because of the clinical mild nature of the phenotypes we performed an in
vivo BH4 loading test. This was positive in all tested patients, which indicates that they are likely to respond to
the coenzyme in vivo. We also analysed the environment of each mutation site in the available crystal
structures of PAH by using molecular graphics tools. The structural alteration produced by each mutation was
elucidated and correlated to the mutated properties of the mutant enzymes. All the data obtained
demonstrate the disease-causing nature of the ﬁve novel variants.
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Hyperphenylalaninemia (HPA; OMIM 261600) is themost frequent
disorder of amino acid metabolism and is mostly due to recessive
mutations in the gene that encodes phenylalanine hydroxylase (PAH:
EC 1.14.16.1) [1–3]. This enzyme, which is mainly expressed by the
liver, converts L-phenylalanine to L-tyrosine in the presence of the
essential cofactor tetrahydrobiopterin (BH4). FewHPA cases are due to
defects in the biosynthesis or regeneration of BH4 [4].
HPA phenotypes are classiﬁed as follows: mild hyperphenylalani-
nemia (MHP or HPA III) when plasma Phe levels of untreated subjects
are between 120 and 600 μM; mild phenylketonuria (MPKU or HPA II)
when untreated plasma Phe levels are between 600 and 1200 μM; and
classical phenylketonuria (PKU or HPA I) when untreated plasma Phe
levels are N1200 μM(http://www.bh4.org/BH4_Deﬁciency_Nomenclature.
asp). HPA patientswith a Phe plasma levelN360 µMmust adhere to a Phe-
restricted diet throughout their lives to prevent the neurotoxic effects ofe Biotecnologie Mediche, Uni-
0131 Naples, Italy. Tel.: +39 081
ll rights reserved.Phe and its metabolites. An increasing number of PAH patients have been
shown to beneﬁt from BH4 supplementation, which in several cases can
substitute dietary restrictions [5–7]. Patients who may beneﬁt from BH4
supplementation can be identiﬁed with the BH4 loading test and by the
presence of mutations found to be associated with the BH4-responsive
phenotype [2,8–10].
To date,more than 500 gene variants have been identiﬁed in the PAH
gene (PAHdb Mutation Analysis Consortium database, at: www.pahdb.
mcgill.ca) [11] that contains 13 exons spread over 80 kb. A number of
PAH mutations are associated with a speciﬁc metabolic phenotype. For
example, some “mild” PAHmutations reduce the afﬁnity of the enzyme
for BH4 and cause the BH4-responsive phenotype [12,13]. Data
regarding the phenotypic impact of other mutations are either lacking
or controversial (http://www.pahdb.mcgill.ca). This is particularly the
case of novel mutations, which are also difﬁcult to identify as disease-
causing mutations because of the lack of functional analyses [14].
PAH mutations are very heterogeneous in Italy. We recently
identiﬁed 60 different gene variants in 126 PAH patients from
Southern Italy. We described ten novel mutations, four of which are
disease-causing (two nonsense, one splicing and one deletion). The
others were missense mutations and we suggested they may be
disease-causing [15].
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enzyme in the bound and unbound states [16–18]. Human PAH has a
tetrameric architecture with each subunit consisting of three domains:
an N-terminal regulatory domain (residues 1–142) containing an α/β
sandwich, a large catalytic domain (residues 143–410 with an α/β fold),
andaC-terminaldomain that is responsible for tetramerization (residues
411–452). The PAH tetramer is a dimer of dimers, with the tetramer core
formed by four α-helices (one from each subunit) tightly packed in an
antiparallel coiled-coilmotif. Structural investigations of disease-causing
mutant enzymes have often revealed correlations between the 3D
structure and the impaired functioning of PAH in PKU [19–22].
In this study, we expressed ﬁve proteins, each containing one of the
ﬁve novel mutations (p.N223Y, p.R297L, p.F382L, p.K398N, p.Q419R)
previously identiﬁed by our group, to investigate the in vitro PAH
activity of the mutant enzymes. We also studied the BH4 response in
vivo using the BH4 loading test in patients bearing these mutations. In
addition, we analyzed the structural perturbations induced by the
mutations within the framework of PAH crystal structures.
2. Materials and methods
2.1. Mutagenesis
PAH mutant constructs were derived from the wild-type PAH expression plasmid
pcDNA3, kindly provided by Prof. P. Knappskog (University of Bergen, Norway) andFig.1. Schematic representation of PAH structure. A: The localization of the ﬁvemutations is r
residue 403 is also shown (mutation p.R297L is in cis with p.A403V). The catalytic domain, th
green, respectively. BH4 cofactor is drawn in yellow, thienylalanine in cyan and Fe ion as
tetramerization domains (PDB code 2pah). Dimers are coloured blue/cyan and red/orange. C:
displayed by Asn223 (magenta) in the β-turn 220–223 are represented by dotted lines. D:
(magenta) are shown. The Arg71 residue is also shown, with its main-chain oxygenwithin H-
Tyr277, His146) are highlighted in the substrate-bound structure (PDB code 1kw0). The sub
Lys398 site. The negatively-charged side-chains close to Lys398 (magenta) are shown. In the
site. Two Gln419 (magenta) residues at the dimer interface are shown with the positively-cProf. P. Waters (McGill University–Montreal Children's Hospital Research Institute,
Montreal, Canada). Each mutation was introduced into the wild-type expression
plasmid using mutagenic primers and the Transformer II kit (Clontech, Palo Alto, CA).
The resulting clones were sequenced to verify the introduction of each single
mutation.
2.2. Expression studies
Tenmicrograms of wild-type andmutant cDNA expression vectors were introduced
into 1.6×106 of humanHEK293 cells using calcium phosphate (ProFection®Mammalian
Transfection System-Calcium Phosphate, Promega Italia, Milan, Italy). Forty-eight hours
after transfection, the cells were harvested by trypsin treatment, washed twice with
150 mM NaCl, resuspended in the same buffer and frozen–thawed 6 times. All
transfections were performed in triplicate. Each triplicate was assayed for total protein
content using a protein assay kit (Biorad, Richmond, CA, USA). Parental vector pcDNA3,
without insert, was transfected as negative control. We co-transfected 10 μg of a
construct carrying a β-galactosidase reporter gene as a control for transfection
efﬁciency. Forty-eight hours after transfection, total RNA was isolated using a standard
protocol and RT-PCR analysiswas performed using speciﬁc primers; the resulting cDNAs
were sequenced.
2.3. Production of polyclonal antibody and Western blot analysis
A synthetic peptide, based on the human PAH amino acid region (NH2-Phe-Gly-
Leu-Gly-Arg-Lys-Leu-(Ser-Phospho)-Asp-Phe-Gly-Gln-Glu-Thr-Ser-Tyr-Ile-Glu-Asp-
Asn-Cys-COOH), was used to immunize rabbits. PAH antiserum was precipitated with
ammonium sulphate and the antibodies were puriﬁed on a protein A-Sepharose
column. Immunoblotting experiments were performed using 10 µg of protein extracts
electrophoresed on a 10% SDS-PAGE gel as previously reported [23].epresented by red spheres in the composite monomeric model (see text); the position of
e regulatory domain, and the tetramerization domain are shown in blue, magenta, and
a grey sphere. B: The tetrameric model of human PAH containing the catalytic and
Asn223 site. Segment 217–224 is drawn in ball-and-stick form. The stabilizing H-bonds
Arg297 site. The negatively-charged side-chains (Glu422 and Asp415) close to Arg297
bond distance of Arg297. E: Phe382 site. Phe382 (magenta) and nearby residues (Tyr356,
strate analogue, thienylalanine (cyan), and the BH4 cofactor (yellow) are also shown. F:
dimer, the H-bond between Glu397 (Cα12) and Ser439 (Tα1) is also drawn. G: Gln419
harged Arg241 residues nearby.
Table 1
Biochemical phenotype and PAH genotype of HPA III patients
Patient ID Serum Phe (µmol/L) Allele A1 Allele A2 a
12 242 c.165delT p.N223Y
74 242 p.R243X p.R297L+p.A403V
96 182 p.R252W p.F382L
82 242 c.442-5CNG p.K398N
135 205 p.S231P p.Q419R
a
Mutations studied.
Fig. 2. RT-PCR (panel A) and Western blot analysis (panel B) in transfected human
HEK293 cells. A: Forty-eight hours after transfection, total RNA was extracted for RT-
PCR analysis; an 871-bp region of PAH cDNA was present in all samples (2 to 7)
examined but not in untransduced cells (lane 1), or in an RT-PCR negative control (water
lane 8). B: a 50-kD band was detected on immunoblots of cells transduced with wild-
type PAH (lane 2) but not in untransduced cells (lane 1). Lane 1: Untransduced cells; 2:
Wild type; 3: p.F382L; 4: p.K398N; 5: p.R297L; 6: p.N223Y; 7: p.Q419R; 8: RT-PCR
negative control (water).
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For each transfection, PAH activity was assayed on 50 µg of proteins, in duplicate, as
previously reported [24]. This testmeasures the amount of 14C radiolabeled Phe converted
to Tyr that were subsequently separated by thin-layer chromatography (TLC). Enzyme
activity of the wild-type and mutant PAH constructs was measured; the mean PAH
activities were calculated from the three sets of transfection data. The residual activities of
mutant PAH enzymes were expressed as a percentage of wild-type enzyme activity and
normalized to transfection efﬁciencies based on replicate β-galactosidase activities.
2.5. BH4 loading test
Patients (legal tutors for minors) provided informed consent to the BH4 loading test,
which was performed according to international guidelines [12]. Brieﬂy, a watery solution
of 20 mg/body kg of (6R)-5,6,7,8-Tetrahydro-L-Biopterin (Schircks Laboratories, Jona,
Switzerland)was given orally 30min before feeding. Blood samples in EDTAwere drawn 0,
2, 4, 6 and8h later, andPheserumconcentrationwasmeasured.Patients ate as usual during
the test. A patient is considered “responder” if the Phe serum concentration decreases
more than 30% 8 h after BH4 load, and “fast responder” if the decrease occurs after 2 h.
2.6. Structural analysis
The effect of the mutations on the 3D structure was investigated by analysing the
structural environment of each substituted residue in the PAH crystal structures
deposited in the Protein Data Bank (PDB). Human PAH is a homotetramer with each
subunit consisting of three domains. A dimeric form also exists in equilibrium with the
tetrameric form. Since no crystal structure of any full-length tetrameric/dimeric PAH is
available, different models were used to study the isolated catalytic domain (human
PAH; PDB code 1kw0), the contact interface between the catalytic and regulatory
domain (rat PAH; PDB code 1phz) and the oligomeric interfaces (human PAH; PDB code
2pah). A composite full-length monomeric model was built by superimposing the
respective catalytic domain regions (Fig. 1A). The notation for the secondary structure
elements mentioned in the text refers to the assignment by Erlandsen and Stevens [19].
3. Results
3.1. Mutation features and structural localization
Table 1 shows the PAH genotype, clinical and biochemical classiﬁca-
tion of the ﬁve HPA patients bearing on allele A2 the PAH missenseTable 2











6 667ANT N223Y None Catalytic/β-turn (220-223) 5





11 1146CNG F382L None Catalytic / Long loop preceding
Cα12 (392–403)
4





12 1256ANC Q419R None Tetramerization / Loop (415–
420) connecting two β-strands
1
⁎According to the nomenclature of the composite model [17].
§Deduced from data deposited in the PDBsum database (ID: 2pah) in the range from 1 (varmutations p.N223Y, p.R297L, p.F382L, p.K398N, and p.Q419R. All
patients were classiﬁed as HPA III; their serum Phe levels at diagnosis
ranged between 182 and 242 μM. Table 2 shows themain features of the
ﬁve mutations. Some nucleotide changes involve a codon that contains
other previously reported gene variants (http://www.pahdb.mcgill.ca).
As shown in Fig. 1A, four of the ﬁve mutations are located in the
catalytic domain (p.N223Y, Fig. 1C; p.R297L, Fig. 1D; p.F382L, Fig. 1E;
p.K398N, Fig. 1F) and the remaining one in the tetramerization domain
(p.Q419R, Fig. 1G). To evaluate the structural implications of the
missensemutations, we examined the 3D localization of the substituted
residues in detail, taking into account the full tetramer (Fig. 1B). The
structural alterations of the mutation sites are summarized in Table 2.
The c.667ANT nucleotide transversion changes the polar Asn residue
at position223 into thepolar, aromatic Tyr residue (p.N223Y). Asn223 is a
moderately conserved amino acid.Mutationp.R297Lwas identiﬁed in cis
with mutation p.A403V (Table 1), which is widely found in PAH patients
[15]. The c.890GNT nucleotide transversion changes the charged Arg
residue at position 297 into the apolar, aliphatic Leu residue (p.R297L).
Arg297 is a moderately conserved amino acid. It is located in the α-helix
Cα8 at the dimer interface (Fig. 1D).n
Structural contacts in WT / Consequent alterations in mutated enzyme
N223 is located in a solvent-exposed β-turn (residues 220–223) connecting
α-helices Cα4 and Cα5 (Fig. 1C). N223 H-bonds to G218 oxygen / Loss of a H-bond;
Tyr exposure
R297 points toward (∼4 Å) negatively-charged residues (E422 and D415) of the
other subunit of the dimer (Fig. 1D). In the structure (PDB code 1phz), R297 forms
a salt bridge with E422 and a H-bond with R71 oxygen in the regulatory domain
of the other subunit of the dimer / Loss of polar interactions at the dimer interface
F382 forms aromatic interactions (~3.7 Å) with Y356. In the substrate-bound state,
it is close to Y277 that in turn displays contacts with H146 (Fig. 1E) / Loss of
aromatic interactions
K398 points toward a hydrated interface in a negatively-charged surrounding and
makes ionic interactions with D394 and E390 within 6 Å (Fig. 1F). In the tetramer,
the Cα12 helix is connected to the Tα1 helix (430–449) of another subunit via a
H-bond (E397...S439) / Perturbation of charge distribution at the subunit
interface and possible interference with the correct positioning of the Cα12 helix
Q419 lies in a rather hydrated region on the dimer interface, close to R241 on the
same subunit (Fig. 1G). In the substrate-bound structure, it is close to Q419 on the
other subunit of the dimer / Unfavourable ionic interactions at the dimer interface
iable) to 9 (conserved).
Fig. 3. Residual enzymatic activity of PAH mutants expressed as percent of wild-type PAH activity. The columns show the mean value and the standard deviation derived from three
different transfections, for each construct.
Fig. 4. Temporal decrease of serum Phe concentrations after 20 mg/kg BH4 loading test.
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382 A. Daniele et al. / Biochimica et Biophysica Acta 1782 (2008) 378–384The c.1146CNG nucleotide transversion changes the apolar,
aromatic Phe residue at position 382 into the aliphatic Leu residue
(p.F382L). Phe382 is not strictly conserved. In fact, it is frequently
replaced by an aromatic Tyr residue. Phe382 is located at the end of
the loop 378–382, near the entrance to the active site. The c.1194ANC
nucleotide transition changes the polar, charged Lys residue at
position 398 into the polar Asn residue (p.K398N). Lys398 is a
conserved amino acid. The c.1256ANC nucleotide transition in exon 12
changes the polar Gln at position 419 into the polar, charged Arg
residue (p.Q419R). Gln419 is a poorly conserved amino acid.
3.2. Functional analysis and expression studies by RT-PCR and Western
blot
We expressed in vitro ﬁve proteins containing the missense
mutations p.N223Y, p.R297L, p.F382L, p.K398N, p.Q419R. The p.R297L
mutation, identiﬁed in cis together with the well characterized p.
A403Vmutation, was reproduced in a recombinant protein as the sole
mutation (Table 1).
The RT-PCR (Fig. 2A) showed a fragment, representing an 871-bp
partial region of PAH mRNA, in the wild-type and in all mutant
constructs examined (lanes 2–7), but not in the untransduced cells
(lane 1) or in the RT-PCR negative control (water lane 8). We identiﬁed
PAH mutant polypeptides in transfected HEK293 cell extracts by
immunoblot analysis using the anti-PAH serum (Fig. 2B). The
monomeric form of the enzyme appeared as a 50-kD band, with
different intensities in cells transfected with the wild-type enzyme
(lane 2) as compared with mutants (lanes 3–7), but was absent in the
untransduced cells (lane 1).
PAH enzyme assay was performed, in three independent experi-
ments, on total protein extracts harvested 48 h after transfection. As
shown in Fig. 3, the residual enzyme activity in cells expressing
mutant cDNAs was 70% (p.N223Y), 42% (p.R297L), 56% (p.F382L), 55%
(p.K398N) and 71% (p.Q419R) that of the wild-type enzyme activity.
There was no enzyme activity in the untransduced cells.
3.3. BH4 loading test
Fig. 4 shows the results of theBH4 loading test inpatients bearing the
genotypes [p.N223Y]+[c.165delT] (magenta line and stars), [p.R297L+p.
A403V]+[p.R243X] (cyan line and diamonds), [p.K398N]+[p.442-
5CNG] (red line and triangles) and [p.Q419R]+[p.S231P] (black line
and squares). Patient [p.A403V]+[c.184delC] (blue line and circles) is a
good responder who served as a positive control in the test because
c.184delC is a null mutation and p.A403V is an in vivo responsive
mutation [25]. The analysed patients proved to be “responders” and
even “fast responders” since the decrease in serum Phe concentration
(from 61% to 87%) occurred already 2 h after BH4 load. The patient
bearing the p.F382Lmutationwas not tested because his parents did not
give consent.
4. Discussion
Five new PAH mutations (p.N223Y, p.R297L, p.F382L, p.K398N,
p.Q419R) were previously identiﬁed by our group in a population of
HPA patients from Southern Italy (Table 1) [15]. Thesemutations can be
considered “mild”, because theywere found in compoundheterozygote
patients affected by a mild phenotype and bearing a “severe”mutation
(www.pahdb.mcgill.ca) on the other allele (allele A1 in Table 1) [25]. In
particular, the missense mutations p.R252W and p.S231P were pre-
viously described as severe mutations [11]. The remaining ones are
severe mutations leading to an inactive PAH protein (c.165delT, p.
R243X, c.442-5CNG) [11].
On a molecular level, in our patients, the PAH tetramer may be
formed fromvarious combinations of mutated alleles (Table 1). The two
homotetramers (A1)4 and (A2)4, and the heterotetramers (A1)1(A2)3,(A1)2(A2)2 and (A1)3(A2)1 can be formed at variable ratios, depending
on the effects generated by mutations (i.e. folding defects, reduced
stability or lowamount of expression) [26]. In fact, co-expression of both
mutants from twomutated alleles resulted in activity values in between
thoseof singlemutants [26]. In our patients bearing a severemutation in
allele A1, the functionality of the PAH tetrameric enzymewould mainly
result from the novel mutations in allele A2. The resulting enzymes,
being embodied in homo- or heterotetrameric proteins, may inﬂuence
the overall in vivo activity [26].
In this work, we reproduced in vitro the ﬁve mutant enzymes and
measured the PAH catalytic activity. The assays showed an activity
decrease to between 42% and 71% that of the wild-type protein.
Western blot analysis showed that the ﬁvemutated constructs yielded
a relatively normal amount of regular-sized PAH polypeptides. This
indicates that these mutations do not induce changes that lead to
increased degradation of themutants nor to alteration of transcription
and translation processes. Therefore, the testedmutations are disease-
causing and the observed decreased enzymatic activity well correlates
with the mild patient phenotype.
Some residual PAH activity is a prerequisite for BH4-responsiveness
[13] but BH4-responsiveness can only be established with an in vivo
test. We therefore veriﬁed BH4 responsiveness for the studied HPA
patients, some of whom (ID 12, 74, 82, Table 1) may be considered
functionally hemizygous (coupled to a null mutation). In all cases, BH4
supplementation resulted in a relevant decrease (N30%) in serum Phe
concentrations, which remained low up to 8 h after BH4 challenge. The
BH4 responsemight be the result of a correction by BH4 of the kinetics
of the PAH mutant and/or of stabilization defects because the mutant
activity is decreased and the mutations might affect the structural
stability [18,22].
HPA is responsive to BH4 supplementation in vivo in more than
70% HPA phenotypes [2]. Infants undergoing BH4 treatment may be
fed a less rigid PKU-restricted diet, with consequent positive effects on
weight gain and quality of life [5–7]. Moreover, this treatment
improves intellectual development especially in patients who have
difﬁculty in adhering to a semisynthetic Phe-restricted diet [6]. As the
BH4 positive response requires some residual PAH activity, BH4 is
believed to activate the PAH enzyme [27]. Indeed, classiﬁcation of
BH4-responsive patients, based on genotype and biochemical pheno-
type, and elucidation of the molecular mechanism underlying BH4-
responsiveness are crucial for PKU treatment. Various mechanisms
have been implicated in BH4-responsiveness [22,28]: increased
enzyme activity [2,12,22,27] correction or compensation of the BH4
decreased afﬁnity, protection towards catalytic inactivation and
chaperone-like activity that, by stabilizing the protein, protects it
from proteolytic degradation [2,3,22]. In addition, BH4 supplementa-
tion may restore the optimal concentration of BH4 cofactor in
hepatocytes [29,30]. In all cases, BH4 responsiveness is dependent
on the genotype, even though in some cases the genotype is not a
reliable predictor of phenotype [9]. The latter authors reported a case
of a patient bearing two null mutations on both alleles who was
responsive to BH4 treatment. Generally, there is no single nor simple
explanation for each patient because each presents his/her own
complex phenotype that requires an ad hoc therapeutical protocol.
However, new therapeutic strategies that monitor the safety and the
response to long-term treatment have recently been reported
[9,10,31].
Previous studies on structure/function correlations showed that
the disease-causing mutations are spread throughout the protein
structure, with a certain number localised at dimer/tetramer inter-
faces. This ﬁnding highlights the relevance of interactions among
subunits for the correct functioning of PAH [16,17]. The structural
examination of the ﬁve PAH mutants, which we describe, revealed
that the substituted residues are not directly involved in the active site
or in the cofactor binding site. Mutations at positions 223 and 382
perturb the local structure of regions that are involved in substrate-
383A. Daniele et al. / Biochimica et Biophysica Acta 1782 (2008) 378–384induced molecular motions; whereas mutations at position 297, 398
and 419 disturb the dimer/tetramer interfaces. All the substitutions
resulted in an enzyme with decreased residual catalytic activity
compared to the wild-type enzyme.
The p.N223Y substitution is found in a region that may be critical
for substrate-triggered molecular motions [17,18,32]. Indeed, it has
been proposed that this residue is the centre of an intra-domain
hinge-bending region associated with the conformational transition
of PAH induced by L-Phe substrate binding [18,32]. In all available PDB
structures, the Asn223 side-chain nitrogen is H-bonded to the main-
chain Gly218 oxygen. This interaction adds further stabilization to the
β-turn (Table 2, Fig. 1C). The change to Tyr would result in the loss of
this H-bond, thereby probably destabilizing the local structure. A
further perturbation could be caused by the exposure of the Tyr
aromatic ring to the surface.
The p.F382L replacement might affect the accessibility of the
substrate in the active site. Indeed, Phe382 is located at the end of
the loop region 378–382, which covers the entrance to the active site.
This loop is quite ﬂexible in the absence of substrate and becomes
more ordered when bound to the pterin cofactor and the L-Phe
substrate. In the latter case, Phe382 forms aromatic interactions
(within 3.7 Å) with Tyr277 thereby protecting the substrate from the
solvent. In both the substrate-free and the substrate-bound structure,
Phe382 forms aromatic interactions with Tyr356, whereas Tyr277
forms van der Waals interactions with His146. Upon substrate
binding, the relative approaching of Phe382 and Tyr277 results in a
network of hydrophobic interactions (Fig. 1E). Substitution of the
aromatic Phe382 with a less bulky and aliphatic Leu residue would
impair the efﬁciency and stabilization of the side-chain packing upon
substrate binding.
Themutations (p.R297L, p.K398N and p.Q419R) perturb the dimer/
tetramer architecture and hence may destabilize the enzyme. In the p.
R297L enzyme, replacement of the Arg side-chain by an apolar group
would disrupt the dimer-stabilizing electrostatic and polar interac-
tions. The Arg side-chain is indeed close to acidic residues from the
other subunit of the dimer. It can also engage a H-bond with a main-
chain oxygen from residue 71 in the regulatory domain (Table 2). It is
noteworthy that in our patients p.R297L was identiﬁed in cis with the
p.A403V substitution on the same allele (Table 1). The p.R297L and
p.A403V mutation sites are far apart (about 19 Å). Ala403 is located at
the end of α-helix Cα12 (Fig. 1A), close to other apolar residues,
namely Ala306 and Ala309 belonging to Cα8. The p.A403V substitu-
tion might affect the close packing of Cα8 and Cα12 helices by
introducing a larger, β-branched, Val residue at the helix–helix
interface. This results in a further reduction of dimer stability. Two
other mutations at position 297 are reported in the PAH database,
p.R297H and p.R297C. The database also includes a unique case of a
patient with the [p.R297C]+[p.Y356X] genotype and a moderate
phenotype (HPA II). Because mutation p.Y356X is a null mutation, it is
conceivable that mutation p.R297C induces a moderate reduction of
enzyme activity, consistent with dimer destabilization.
In the p.K398N enzyme, substitution of Lys with a smaller and
uncharged Asn would perturb the charge distribution at the tetramer
interface. Indeed Lys398 protrudes toward a dimer hydrated interface
in a negatively-charged surrounding, the acidic residues Asp394 and
Glu390 being within 6 Å (Fig. 1F). Lys398 belongs to the Cα12 helix
(392–403) and contributes to helix stabilization through ionic
interactions with residues Glu390 and Asp394. It is noteworthy that
the Cα12 helix is a key secondary structure element that undergoes
signiﬁcant motion upon substrate binding [17,32]. Furthermore, in the
tetramer, the Cα12 helix is directly connected to Ser439 of the Tα1
helix (430–449) of another subunit, via a H-bond formed by Glu397,
the residue preceding K398 (Table 2, Fig. 1F). The substitution may
therefore also interfere with correct positioning of the Cα12 helix,
which is involved in interactions with the tetramerization domain,
and in molecular motions [14].In the p.Q419R enzyme, replacement of Gln with a charged Arg
would increase the charge repulsion between basic residues of the same
subunit (Table 2). In the homotetramer (A2)4, replacement p.Q419R
would also result in a close localization of two corresponding Arg419
residues on different subunits of the dimer (Fig.1G). The replacement of
Gln with a charged Arg residue may hamper oligomerization.
In conclusion, all the data reported herein support the pathologic
nature of the ﬁve studied variants. In fact, the enzyme activity exerted
by the recombinant protein variants was from 42% to 71% that of the
wild-type enzyme, which well correlates with the mild hyperpheny-
lalaninemia found in our patients. Accordingly, the analysis carried
out in silico shows that the structural alterations do not directly affect
the binding site of either the substrate or the coenzyme — rather they
interfere with favourable interactions at the molecular surface or at its
quaternary structure, and hence may destabilize structural integrity.
Finally, the beneﬁcial effect of BH4 supplementation in patients
indicates that altered activity/stability could be partially reversed,
thus supporting the not severe nature of HPA in patients bearing the
variant proteins studied in this report.
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